Autopsy report · NCT00610311

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

“The study was terminated due to low accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 1 month before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Metastatic Melanoma; Skin Cancer

Interventions

cyclophosphamide; fludarabine phosphate; Aldesleukin; ALVAC gp100 Vaccine; anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)

Participants

3

Sites

1

Countries

United States

Trials that died the same way

• Pembrolizumab + Idelalisib for Lung Cancer Study
  “The study was terminated due to poor accrual.” (97% match in meaning)
• Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
  “Study terminated due to low accrual.” (95% match in meaning)
• Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
  “Study was terminated due to lack of accrual.” (92% match in meaning)
• Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension
  “Study has been terminated due to poor accrual.” (92% match in meaning)
• Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
  “Study was terminated due to poor accrual” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.